Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
study ends around

Description

Summary

This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Official Title

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases

Details

Keywords

Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma, Carcinoma, Avelumab, Monoclonal Antibodies, Peripheral Blood Collection

Eligibility

Locations

  • University of California Irvine Chao Family Comprehensive Cancer Center
    Orange California 92868 United States
  • Fred Hutch/University of Washington Cancer Consortium
    Seattle Washington 98109 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of Washington
ID
NCT03271372
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 101 people participating
Last Updated